INTRODUÇÃO: sangramento por coagulopatia é problema comum durante o transplante hepático (TH). O uso adequado da monitorização da coagulação pode reduzir a transfusão de hemocomponentes, como o Plasma Fresco Congelado (PFC). Exames Convencionais da Coagulação (ECC), tais como Tempo de Protrombina (TP) e Tempo de Tromboplastina Parcial Ativada (TTPa), são os testes mais amplamente utilizados para monitorizar a coagulação durante o TH, mas algumas limitações têm sido apontadas acerca do seu uso em pacientes cirróticos. OBJETIVO: investigar o uso de ECC como variáveis preditoras da indicação de transfusão de PFC durante o TH em pacientes cirróticos. MÉTODO: analisou-se coorte histórica de 297 transplantes hepáticos com enxertos provenientes de doadores cadáveres. Foram incluídos receptores cirróticos de uma única instituição durante nove anos (2002-2010). A infusão profilática de ácido épsilon-aminocaproico (20 mg/kg/h) e outros pré-requisitos hemostáticos foram mantidos na cirurgia. O TP [expresso na forma de Percentual de Atividade da Protrombina (TP%) e de Relação Normalizada Internacional (INR)] e o TTPa foram medidos no pré-operatório e no fim de cada fase do TH. Os participantes só receberam transfusão de PFC quando se diagnosticou coagulopatia, independentemente dos resultados dos ECC. Os pacientes foram distribuídos em dois grupos, de acordo com a ocorrência de transfusão intraoperatória de PFC. Examinou-se o comportamento dos resultados dos ECC durante a cirurgia. Analisaram-se os fatores de risco para a transfusão de PFC por análises uni e multivariada. Os resultados pós-operatórios de ambos os grupos foram comparados. A acurácia dos ECC para predizer o uso de PFC em cada fase da cirurgia foi investigada por curvas ROC. Além disso, pontos de corte dos ECC não associados à coagulopatia foram calculados para cada fase da cirurgia. RESULTADOS: a análise multivariada demonstrou que hematócrito pré-operatório (odds ratio [OR] = 0,90, P < 0,001), fibrinogênio pré-operatório (OR = 0,99, P < 0,001) e ausência de carcinoma hepatocelular (OR = 3,57, P = 0,004) foram as únicas variáveis preditoras independentes para a transfusão de PFC durante o TH. As mortalidades precoce e tardia, a permanência em UTI e a incidência de reoperações por sangramento microvascular foram semelhantes entre os grupos. Os ECC demonstraram baixa acurácia global para a predição de transfusão de PFC durante o TH (as áreas sob as curvas ROC não chegaram a 70%, independentemente do teste da coagulação e do momento da aferição). Pontos de corte de ECC com alta especificidade para a não transfusão de PFC foram determinados em cada fase do TH para TP% (39,4, 27,8 e 20,3), INR (2,14, 2,62 e 3,52) e TTPa (50,5, 80,2 e 119,5 segundos). CONCLUSÕES: os únicos preditores independentes para a transfusão de PFC durante o TH foram hematócrito pré-operatório, fibrinogênio pré-operatório e ausência de carcinoma hepatocelular. Os ECC demonstraram baixa correlação com a transfusão intraoperatória de PFC, independentemente do momento da coleta ou dos pontos de corte adotados / BACKGROUND & AIMS: Bleeding due to coagulopathy is a common problem during liver transplantation (LT). Coagulation monitoring may reduce transfusion of blood components, including Fresh Frozen Plasma (FFP). Conventional coagulation assays (CCA), like Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT), are the most widely employed tests to monitor coagulation during LT, but some limitations have been assigned to their use in cirrhotic patients. This study investigated the predictive value of these blood coagulation tests in predicting FFP transfusions during LT in cirrhotic patients. METHODS: This historical cohort study analyzed 297 isolated, deceased donor LTs performed in cirrhotic patients from a single institution during a nine-year period (2002 - 2010). Prophylactic infusion of epsilon-aminocaproic acid [EACA] (20 mg/kg/h) and other hemostatic requirements were maintained intraoperatively. PT [expressed as Activity Percentage (PT%) and International normalized ratio (INR)] and aPTT [expressed in seconds] were measured preoperatively and by the end of each phase of LT. Hemostatic blood components were transfused only in case of coagulopathy. Patients were divided in two groups according to intraoperative FFP transfusion: FFP group and Non-FFP group. Behavior of CCA results during LT were examined in both groups. Univariate and multivariate analyses of risk factors associated with FFP transfusion were performed. Post-operative outcomes were compared between groups. Accuracy of CCA to predict FFP transfusions was investigated using receiver operating characteristic (ROC) curves. Also, alert values of CCA unassociated with coagulopathy in each phase of surgery were calculated. RESULTS: Multivariate analysis showed that preoperative hematocrit (odds ratio [OR] = 0.90, P < 0.001), preoperative fibrinogen (OR = 0.99, P < 0.001) and absence of hepatocellular carcinoma (OR = 3.57, P = 0.004) were the only significant predictors for FFP transfusion. Short- and long-term survival, ICU stay and incidence of early reoperations for bleeding were similar between the groups. CCA demonstrated poor overall accuracy for predicting FFP transfusions (area under the ROC curves did not reach 0.70, irrespective of assay and of phase of sampling). High-specificity values of CCA unassociated with coagulopathy in each of 3 phases of LT were identified for INR (2.14, 2.62 and 3.52), PT% (39.4, 27.8 and 20.3%) and aPTT (50.5, 80.2 and 119.5 seconds). CONCLUSIONS: the only significant predictors for FFP transfusion were preoperative hematocrit, preoperative fibrinogen and absence of hepatocellular carcinoma. CCA, regardless of adopted cutoffs and of time of sampling during LT, have poor correlation with intraoperative FFP transfusion

T1rho弛豫是旋轉坐標系中的自旋晶格弛豫，它決定橫向磁化向量在存有自旋鎖定射頻脈衝情況下的衰減，自旋鎖定脈衝與橫向磁化向量同向。T1rho磁共振成像對於低頻運動過程敏感，故可研究水與其周大分子物質環境間的交互作用，有鑒別組織內早期生化改變的潛力。 / 衰老與慢性高血壓是常見腦退行性疾病的兩個主要危險因素。但是正常腦衰老過程及慢性高血壓兩個因素與腦組織T1rho是否有相關性，尚缺乏研究。序貫性測量SD老鼠自5至15月齡、WKY（血壓正常）和SHR（患有自發性高血壓）老鼠自6至12月齡的雙側丘腦、海馬、和皮質的腦組織T1rho值。發現三組老鼠的丘腦、海馬及皮質的T1rho均隨年齡增長而增高；且SHR的顯著高於WKY老鼠。 / T1rho值與椎間盤退變等級的相關性已有報導。但相比T2值，T1rho在評價椎間盤退變方面是否優於或如何優於T2值尚缺乏研究。將椎間盤髓核及纖維環的T1rho和T2值與5級和8級椎間盤退變等級系統做比較；發現髓核的T1rho及T2與椎間盤退變等級的相關性均呈二次函數降低，且無顯著差別(P=0.40)。纖維環的T1rho及T2與椎間盤退變等級的相關性呈線性函數降低，T2降低的斜率明顯比T1rho降低的斜率要平坦(P<0.001)。故T1rho值比T2值更加適合評價纖維環退變，而兩者在評價髓核時相似。 / 肝纖維化是幾乎所有慢性肝病的常見特徵，包括大分子物質在細胞外基質的沉積。選用四氯化碳CCl4腹腔注射6周來製造肝纖維化模型。肝臟T1rho在注射後的第二天輕度上升，然後持續上升，直到注射六周後T1rho達最高值，此後T1rho隨CCl4注射停止而降低。顯示T1rho磁共振成像對於監測慢性注射CCl4誘導的肝纖維化及肝損傷有價值。當沒有明顯肝纖維化時，肝T1rho輕微受水腫及急性炎症的影響。 / 為將肝臟T1rho磁共振成像轉化到臨床使用，我們研究了其可行性，以及正常志願者肝臟T1rho值分佈範圍。發現採用六個自旋鎖定時間來測量健康志願者肝T1rho，結果有較高的可重複性和一致性，肝T1rho平均值為42.5ms，分佈範圍為38.8到46.5ms。採用三個自鎖鎖定時間點掃描，可以減少一半掃描時間，且可以得到可信的肝T1rho值，但採用兩個自旋鎖定時間點則不行。 / T1rho relaxation is spin-lattice relaxation in the rotating frame. It determines the decay of the transverse magnetization in the presence of a spin-lock radiofrequency pulse, which applied along the transverse magnetization. T1rho MRI is sensitive to low frequency motional processes, so it can be used to investigate the interaction between water molecules and their macromolecular environment. T1rho imaging is suggested to have the potential to identify early biochemical changes in tissues. / Aging and chronic hypertension are two major risk factors for common neurodegenerative disease. However, whether normal brain aging and chronic spontaneous hypertensive are associated with brain T1rho values changes were not reported. We longitudinally measured the T1rho value in rat brain of Sprague-Dawley (SD) rats from 5-month to 15-month, and spontaneous hypertensive rats (SHR) with Wistar Kyoto (WKY) rats from 6-month to 12-month. The T1rho values in three brain regions of thalamus, hippocampus, and cortices increased with aging process, and were significantly higher in SHR than WKY rats. / For intervertebral disc, the correlation between T1rho and degenerative grade has been reported. However, whether and how T1rho specifically offer better evaluation of disc degeneration compared with T2 was not studied previously. T1rho and T2 value of nucleus pulposus (NP) and annulus fibrosus (AF) was compared with reference to the five-level and eight-level semi-quantitative disc degeneration grading systems. For NP, T1rho and T2 decreased quadratically with disc degeneration grades and had no significant trend difference (P=0.40). In NP, T1rho and T2 decrease in a similar pattern following disc degeneration. For AF, T1rho and T2 decreased linearly and the slopes of T2 were significantly flatter than those of T1rho (P<0.001). Therefore, the T1rho is better suited for evaluating AF in degenerated disc than T2. / Liver fibrosis, a common feature of almost all causes of chronic liver disease, involves macromolecules accumulated within the extracellular matrix. Male Sprague-Dawley rats received intraperitoneal injection of 2 ml/kg CCl4 twice weekly for up to 6 weeks. Then CCl4 was withdrawn for recovery. The liver T1rho values increased slightly on day 2, then increased further and were highest at week 6 post CCl4 insults, and decreased upon the withdrawal of the CCl4 insult. This study demonstrated that T1rho MRI is a valuable imaging biomarker for liver injury and fibrosis induced by CCl4. Liver T1rho value was only mildly affected by edema and acute inflammation when there was no apparent fibrosis. / To translate liver T1rho MRI to clinical application, the technical feasibility of T1rho MRI in human liver was explored and the normal range of T1rho values in healthy volunteers was determined. We found it is feasible to obtain consistent liver T1rho measurement for healthy human liver with six spin-lock time (SLT) points of 1, 10, 20, 30, 40, and 50ms; the mean liver T1rho value of the healthy subjects was 42.5ms, with a range of 38.8-46.5ms. Adopting 3-SLT points of 1, 20, and 50ms for T1rho measurement could provide reliable measurement and reduce the scanning time, while 2-SLT points of 1 and 50ms do not provide reliable measurement. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Zhao, Feng. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2013. / Includes bibliographical references (leaves 119-143). / Abstracts also in Chinese. / ABSTRACT --- p.i / ACKNOWLEDGEMENTS --- p.vi / LIST OF FIGURES --- p.viii / LIST OF TABLES --- p.xvi / LIST OF ABBREVIATIONS --- p.xvii / CONTENTS --- p.xxi / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- Conventional Magnetic Resonance Imaging --- p.1 / Chapter 1.1.1 --- Basic Principle of Conventional Magnetic Resonance Imaging --- p.1 / Chapter 1.1.2 --- T1 Relaxation --- p.2 / Chapter 1.1.3 --- T2 Relaxation --- p.3 / Chapter 1.2 --- T1rho Magnetic Resonance Imaging --- p.3 / Chapter 1.2.1 --- T1rho Relaxation --- p.3 / Chapter 1.2.2 --- Principle of T1rho Magnetic Resonance Imaging --- p.4 / Chapter 1.2.3 --- Radiofrequency Pulse for T1rho Magnetic Resonance Imaging --- p.5 / Chapter 1.2.4 --- T1rho-weighted Contrast Imaging and Application --- p.10 / Chapter 1.2.5 --- Quantitative T1rho Mapping and Application --- p.11 / Chapter 1.2.6 --- T1rho Dispersion and Application --- p.13 / Chapter 1.3 --- Thesis Overview --- p.14 / Chapter Chapter 2 --- T1rho MRI in brain aging of animal model --- p.19 / Chapter 2.1 --- Introduction --- p.19 / Chapter 2.2 --- Materials and Methods --- p.20 / Chapter 2.2.1 --- Animal Model of Brain Aging --- p.20 / Chapter 2.2.2 --- T1rho Data Acquisition --- p.21 / Chapter 2.2.3 --- T1rho Data Processing --- p.23 / Chapter 2.2.4 --- T1rho Measurement and Statistical Analysis --- p.24 / Chapter 2.3 --- Results --- p.27 / Chapter 2.4 --- Discussion --- p.38 / Chapter 2.5 --- Summary --- p.42 / Chapter Chapter 3 --- T1rho MRI in lumbar disc degeneration of human subjects --- p.43 / Chapter 3.1 --- Introduction --- p.43 / Chapter 3.2 --- Methods --- p.45 / Chapter 3.2.1 --- Subjects --- p.45 / Chapter 3.2.2 --- MR Image Acquisition --- p.46 / Chapter 3.2.2.1 --- T2-weighted MRI --- p.46 / Chapter 3.2.2.2 --- T2 Mapping Imaging --- p.47 / Chapter 3.2.2.3 --- T1rho MRI --- p.47 / Chapter 3.2.3 --- Data Processing --- p.49 / Chapter 3.2.4 --- Data Measurement and Statistical Analysis --- p.49 / Chapter 3.3 --- Results --- p.52 / Chapter 3.3.1 --- Range of T1rho/T2 Values for Discs --- p.52 / Chapter 3.3.2 --- The Relationship between NP T1rho/T2 Values and 8-level Degeneration Grading of Discs --- p.52 / Chapter 3.3.3 --- The Relationship between NP T1rho/T2 Values and 5-level Degeneration Grading of Discs --- p.55 / Chapter 3.3.4 --- The Relationship between AF T1rho/T2 Values and 8-level Degeneration Grading of Discs --- p.58 / Chapter 3.3.5 --- The Relationship between AF T1rho/T2 Values and 8-level Degeneration Grading of Discs --- p.61 / Chapter 3.4 --- Discussion --- p.64 / Chapter 3.5 --- Summary --- p.69 / Chapter Chapter 4 --- T1rho MRI in rat liver fibrosis model induced by CCl4 insult --- p.71 / Chapter 4.1 --- Introduction --- p.71 / Chapter 4.2 --- Materials and Methods --- p.73 / Chapter 4.2.1 --- Animal Preparation --- p.73 / Chapter 4.2.2 --- MR Image Acquisition --- p.74 / Chapter 4.2.2.1 --- T2-weighted MRI --- p.75 / Chapter 4.2.2.2 --- T1rho MRI --- p.75 / Chapter 4.2.3 --- Data Processing --- p.76 / Chapter 4.2.4 --- Data Measurement and Statistical Analysis --- p.78 / Chapter 4.2.5 --- Histology Analysis --- p.79 / Chapter 4.3 --- Results --- p.80 / Chapter 4.3.1 --- T1rho Measurement Reproducibility --- p.80 / Chapter 4.3.2 --- Rat Liver T1rho Values at Different Time Phase --- p.81 / Chapter 4.3.3 --- Relative Rat Liver Signal Intensity on T2WI at Different Time Phase --- p.83 / Chapter 4.3.4 --- Histology Results --- p.84 / Chapter 4.4 --- Discussion --- p.86 / Chapter 4.5 --- Summary --- p.91 / Chapter Chapter 5 --- T1rho MRI in liver of healthy human subjects --- p.93 / Chapter 5.1 --- Introduction --- p.93 / Chapter 5.2 --- Methods --- p.95 / Chapter 5.2.1 --- Subjects --- p.95 / Chapter 5.2.2 --- MR Image Acquisition --- p.96 / Chapter 5.2.2.1 --- T2-weighted MRI --- p.96 / Chapter 5.2.2.2 --- T1rho MRI --- p.97 / Chapter 5.2.3 --- T1rho Data Processing --- p.99 / Chapter 5.2.4 --- T1rho Measurement --- p.100 / Chapter 5.3 --- Results --- p.102 / Chapter 5.3.1 --- T1rho Measurement Reproducibility --- p.105 / Chapter 5.3.2 --- T1rho Value Agreement of the Fasting Status with Post Meal Status --- p.105 / Chapter 5.3.3 --- T1rho Value Agreement for T1rho Maps Constructed by Different Spin-lock Time Points --- p.106 / Chapter 5.3.4 --- T1rho Value Range of Healthy Human Subjects --- p.108 / Chapter 5.4 --- Discussion --- p.108 / Chapter 5.5 --- Summary --- p.113 / Chapter Chapter 6 --- General discussion and further work --- p.115 / References: --- p.119 / LIST OF PUBLICATIONS --- p.138

Made available in DSpace on 2016-01-26T12:51:53Z (GMT). No. of bitstreams: 1 maristeladeberaldini_dissert.pdf: 1301347 bytes, checksum: 7cac2aa1d04033762fd9af3c08299a4b (MD5) Previous issue date: 2006-08-25 / Hepatopulmonary syndrome (HPS) is a clinical triad characterized by the presence of intrapulmonary vascular dilation (IPVD) and arterial hypoxemia with hepatic disease. Liver transplantation constitutes the only cure for HPS; possibly providing a complete reversal of the symptoms. However, an association between HPS and adverse results has been reported with liver transplantation. Data on long-term survival of transplant patients with HPS are scarce. The objective of this study was to evaluate the short-term postoperative complications and short- and long-term survival in the postoperative period of transplant patients with and without HPS. Fifty-nine cirrhotic patients transplanted in the period from October 2001 to May 2004 were evaluated in this study. The patients were divided into two groups: with HPS (HPS Group n = 25) and without HPS (Control group n = 34). IPVD was diagnosed by echocardiogram contrasted using microbubbles. Hypoxemia was defined as D(A-a)O2 &#8805; 15 mmHg. The following variables were considered after liver transplantation: immediate survival (within the hospitalization period after transplantation), late survival (at 48 months), causes of death, time of hospital stay, time of ICU, time of ventilatory support, the necessity of re-intubation and complications. The results were analysed utilizing the following statistical tests: T-test to compare means, the non-parametric Mann-Whitney test to compare medians and ANOVA and chi-squared tests for qualitative variables. A level of significance of 0.05 for &#945; was adopted. The HPS and Control Groups were homogeneous in respect to age (p-value = 0.36; 43.8 ± 12.2 vs. 46.9 ± 13.5) and gender (p-value = 0.47), with a predominance of men in both groups (68 and 78%, respectively). They were also similar in respect to the severity of hepatic disease and the presence of ascitis. The PaO2 was significantly lower (74.9 ± 12.1 vs. 93 ± 6.4 mmHg; P-value < 0.001) and the D(A-a)O2 was significantly higher in the HPS Group compared to the Control Group. There were 10 patients with mild hypoxemia (40%), 11 with moderate hypoxemia (44%) and 4 with severe/very severe hypoxemia (16%) in the HPS Group. There were no significant differences between the groups with and without HPS in relation to early (68% vs. 77%; p-value = 0.27) and late (60% vs. 64%; p-value = 0.67) survival; time in ICU (median 7.0 vs. 5.5; p-value = 0.41); time on ventilatory support (median 38.0 vs. 27.5; p-value = 0.43); re-intubation rate (32.0% vs. 23.5%; p-value = 0.45) and complications (p-value = 0.72) in the immediate post-transplantation period. In conclusion, there were no significant differences in the results of liver transplantation of patients with and without HPS in respect to immediate morbidity or in relation to early and late survival 48 months after the procedure. The predominance of patients with mild and moderate HPS in the group may have influenced our results. / A síndrome hepatopulmonar (SHP) é uma tríade clínica caracterizada pela presença de dilatação vascular intrapulmonar (DVIP) e hipoxemia arterial [D(A-a)O2 &#8805; 15 mmHg] em portadores de doença hepática. O transplante de fígado constitui a única modalidade terapêutica para SHP podendo haver reversão completa do quadro. Porém, tem sido descrita associação entre SHP e resultados desfavoráveis do transplante de fígado. Dados sobre a sobrevida a longo prazo em transplantados com SHP são escassos. O objetivo deste estudo foi avaliar a morbidade pós-operatória precoce e a sobrevida precoce e tardia no período pós-operatório de pacientes transplantados com e sem SHP. Foram analisados, neste estudo transversal comparativo de amostras paralelas, 59 pacientes cirróticos transplantados no período de Outubro de 2001 a Maio de 2004, divididos em dois grupos: com SHP = grupo estudo (n=25) e sem SHP = grupo controle (n=34). A DVIP foi diagnosticada pelo exame ecocardiográfico contrastado com microbolhas. A hipoxemia foi definida como D(A-a)O2 &#8805; 15 mmHg. As seguintes variáveis após o transplante de fígado foram estudadas: sobrevida imediata (ocorrida no período da internação para o transplante), sobrevida tardia (48 meses), causas de óbito, tempo de permanência hospitalar, tempo de permanência em UTI e tempo de ventilação mecânica, necessidade de reentubação e complicações. Os resultados foram analisados utilizando os seguintes testes estatísticos: teste t para comparação de médias, teste não paramétrico de Mann-Whitney para comparação de medianas, ANOVA e teste qui-quadrado para variáveis qualitativas. O nível de significância adotado foi &#945;=0,05. Os grupos SHP e controle foram homogêneos quanto à idade (P=0,36) (43,8 ± 12,2 X 46,9 ± 13,5) e gênero (P=0,47), havendo predominância de homens nos dois grupos (68 e 78%, respectivamente). Foram também semelhantes quanto à causa e gravidade da doença hepática e quanto à presença de ascite. A PaO2 foi significativamente menor (74,9 ± 12,1 X 93 ± 6,4 mmHg; P<0,001) e a D(A-a)O2 foi significativamente maior (30,3 ± 10,6 X 11,0 ± 7,0; P<0,001) no grupo SHP em relação ao grupo controle. Houve 10 pacientes com hipoxemia leve (40%), 11 com hipoxemia moderada (44%) e 4 com hipoxemia grave/muito grave (16%) no grupo com SHP. Os resultados não mostraram evidência de diferença entre os grupos com e sem SHP quanto à sobrevida precoce (68% X 77%; P=0,27) e tardia (60% X 64%; P=0,67); quanto ao tempo de permanência em UTI (mediana 7,0 X 5,5; P=0,41); tempo de ventilação mecânica (mediana 38,0 X 27,5; P=0,43); taxa de reentubação (32,0% X 23,5%; P=0,45) e ocorrência de complicações (P=0,72), no período imediato após o transplante. Podemos concluir que não houve diferença no resultado do transplante de fígado de pacientes com e sem SHP, quanto à morbidade e complicações imediatas, e quanto à sobrevida precoce e aos 48 meses após o procedimento. O predomínio de pacientes com SHP leve e moderada no grupo SHP deve ter influenciado os nossos resultados.

Kam, Kin Ting. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2008. / Includes bibliographical references (leaves 169-192). / Abstracts in English and Chinese. / Chapter 1. --- Abstract --- p.ii / English --- p.ii / Chinese --- p.v / Chapter 2. --- Acknowledgments --- p.vii / Chapter 3. --- Abbreviations and N-glycan representation --- p.viii / Chapter 4. --- Introduction --- p.1 / Chapter 5. --- Review of Literatures --- p.2 / Chapter 5.1. --- Introduction to Liver Fibrosis --- p.2 / Chapter 5.1.1. --- Pathogenesis of Liver Fibrosis --- p.2 / Chapter 5.1.2. --- Changes of liver architecture - basis of liver fibrosis diagnosis --- p.4 / Chapter 5.2. --- Current Diagnosis of Liver Fibrosis - from Biopsy Examination to Serum Test --- p.5 / Chapter 5.3. --- Glycomics and its Potential as Biomarkers --- p.9 / Chapter 5.3.1. --- Overview of Biochemical and Functional Characteristics of Glycan --- p.13 / Chapter 5.3.2. --- N-linked and O-linked Glycosylations - A Valuable Source of Biomarkers --- p.15 / Chapter 5.3.3. --- Glycomics 一 An Uprising Approach for Biomarker Discovery --- p.17 / Chapter 5.3.4. --- Human Proteome Organisation Human Disease Glycomics/Proteome Initiative --- p.19 / Chapter 5.3.5. --- Recent Applications of Glycomics to Biomarker Discovery --- p.20 / Chapter 5.4. --- Current Technologies for Glycomic Study --- p.22 / Chapter 5.4.1. --- MALDI-TOF MS --- p.22 / Chapter 5.4.2. --- Lectin Microarray --- p.25 / Chapter 5.4.3. --- Liquid Chromatography --- p.27 / Chapter 5.4.4. --- Capillary Electrophoresis --- p.29 / Chapter 5.4.5. --- Quantitative Profiling of Tissue Glycome --- p.31 / Chapter 6 --- Project Rationales and Objectives --- p.36 / Chapter 7 --- Section 1: Methodology Development of Quantitative N- glycomic Profiling --- p.37 / Chapter 1. --- Introduction --- p.37 / Chapter 2. --- Method and Materials --- p.39 / Chapter 3. --- Results --- p.46 / Chapter 4. --- Discussion --- p.65 / Chapter 5. --- Conclusion --- p.71 / Chapter 8. --- Section 2: Serum N-glycomic Profile as Biomarker for Liver Fibrosis 一 Pilot Study --- p.73 / Chapter 1. --- Introduction --- p.73 / Chapter 2. --- Method and Materials --- p.75 / Chapter 3. --- Results --- p.79 / Chapter 4. --- Discussion --- p.86 / Chapter 5. --- Conclusion --- p.94 / Chapter 9. --- Section 3: Serum N-glycomic Profile as Biomarker for Liver Fibrosis -Verification Study --- p.96 / Chapter 1. --- Introduction --- p.96 / Chapter 2. --- Method and Materials --- p.98 / Chapter 3. --- Results --- p.104 / Chapter 4. --- Discussion --- p.137 / Chapter 5. --- Conclusion --- p.152 / Chapter 10. --- General Discussion --- p.153 / Chapter 11. --- Conclusion --- p.167 / Chapter 12. --- Original Data --- p.168 / Chapter 13. --- References --- p.169 / Chapter 14. --- Publications --- p.196

O presente trabalho avaliou o papel da solução parenteral de fatores hepatotróficos nutricionais em animais com cirrose submetidos à hepatectomia parcial. Este procedimento é temido nestes animais devido à possibilidade de ocorrência de falência hepática aguda, já que a remoção de um fragmento do fígado reduz ainda mais a capacidade funcional de um órgão já comprometido. Além disso, é conhecido que o fígado cirrótico diminui sua capacidade regenerativa, fato que atrasa a recuperação do animal, bem como também regenera cirroticamente. Esses fatores, aliados, contribuem para uma considerável taxa de mortalidade pós-operatória. Porém, há algumas situações em que estes pacientes precisam ser submetidos a ressecções hepáticas, tais como traumas, infecções e neoplasias. De fato, a presença de hepatocarcinomas representa a maior indicação deste procedimento em fígados cirróticos. Por outro lado, tem-se mostrado que a administração parenteral de solução de fatores hepatotróficos nutricionais (FHN), uma mistura de aminoácidos, vitaminas, sais minerais e hormônios, aumenta consideravelmente a proliferação celular e o tamanho do fígado em animais sadios, com fibrose e com cirrose. Nestes dois últimos, além do crescimento hepático, ocorre também uma importante redução na quantidade de colágeno, significando uma melhora morfológica que, por muitas vezes, resulta em uma melhora funcional. Sendo assim, o objetivo do presente trabalho foi o verificar se o uso de fatores hepatotróficos nutricionais traria também uma melhora morfológica e funcional em animais com cirrose induzida por tiocetamida após uma ressecção hepática de 40%. Utilizou-se 40 ratos (Rattus norvegicus) Wistar fêmeas cuja indução da cirrose foi pela administração intraperitoneal de tiocetamida. Ao final deste período, e após 10 dias de descanso, todos os animais foram submetidos a uma hepatectomia parcial (HP) de 40%. Foram então divididos em dois grupos: um que recebeu intraperitonealmente a solução de fatores hepatotróficos nutricionais durante 12 dias, designado grupo HP+FHN, e outro que recebeu solução fisiológica nas mesmas condições, formando o grupo HP+S. Os seguintes parâmetros foram avaliados no término do período experimental: dados biométricos (peso do fígado, IHS: índice hepassomático e IHC: índice hepatocarcaça), bioquímica hepática plasmática (AST, ALT, fosfatase alcalina, bilirrubina total e albumina), quantificação da densidade volumétrica de colágeno hepático por morfometria, quantificação do índice de proliferação celular por imunohistoquímica para PCNA e expressão de genes pró-fibróticos (MMP2, TIMP1, Cola1 e TGFb1) por PCR em tempo real. De fato, os fígados dos animais do grupo HP+FHN estavam maiores do que os animais do grupo HP+S (aumentos de 8,4%, 5,6% e 8,4% no peso do fígado, IHS e IHC respectivamente), e também apresentaram maior índice de proliferação de hepatócitos (44,9%). Ocorreu também redução de 27,9% na densidade volumétrica do colágeno hepático no grupo que recebeu FHN comparandose com o grupo que recebeu solução salina. Esta redução também foi observada na expressão do gene de colágeno a1, que foi de 53%. Porém, não houve diferença nos demais genes avaliados. Dentre os parâmetros bioquímicos, apenas a fosfatase alcalina mostrou redução. Os resultados obtidos permitem concluir que o uso de FHN acarreta em um aumento da regeneração hepática acompanhado de uma redução da quantidade de colágeno e, esses achados, em conjunto, podem representar uma condição benéfica na recuperação de pacientes com cirrose submetidos à ressecção hepática / The current study evaluated the role of parenteral solution of nutritional hepatotrophic factors in animals with cirrhosis undergoing partial hepatectomy. This procedure is fearful in these animals due to the possibility of acute liver failure, since removal of a liver fragment further reduces the functional capacity of an already compromised organ. Moreover, it is known that cirrhotic liver decreases its regenerative capacity, which impairs the recovery of the animal, and also regenerates cirrhotic. These factors, together, contribute to a considerable rate of postoperative mortality. However, there are some situations when these patients need to be submitted to liver resection, such as trauma, infections and neoplasm. In fact, the presence of hepatocellular carcinoma represents the most important indication of this procedure in patients with cirrhosis. On the other hand, it has been shown that parenteral administration of a solution of the nutritional hepatotrophic factors (NHF), a mixture of amino acids, vitamins, minerals and hormones, significantly increases cell proliferation and liver size in healthy, fibrotic and cirrhotic animals. In the two latter, beyond the liver growth, there is also a significant reduction in the amount of collagen, meaning a morphological enhancement, resulting in a functional improvement. Therefore, the objective of this study was to determine whether the use of nutritional hepatotrophic factors would also lead a morphological and functional improvement in animals with thioacetamide-induced cirrhosis after 40% liver resection. We used 40 rats (Rattus norvegicus) female Wistar whose cirrhosis was induced by intraperitoneal administration thioacetamide. At the end of this period, and after 10 days of rest, all animals were underwent a partial hepatectomy (PH) of 40%. They were then divided into two groups: one that received intraperitoneally a solution of nutritional hepatotrophic factors for 12 days, designated PH+NHF group, and another that received saline under the same conditions, forming the PH+S group. The following parameters were evaluated at the end of the trial period: biometrics (liver weight, HSI hepatossomatic index, and HCI hepatocarcass index), plasmatic liver biochemistry (AST, ALT, alkaline phosphatase, total bilirubin and albumin), quantification of volume density of collagen in liver morphology, quantification of cell proliferation by immunohistochemistry for PCNA and expression of pro-fibrotic genes (MMP2, TIMP1, TGF1 and Cola1) by real-time PCR. In fact, the livers of animals in group PH+NHF were larger than the animals in PH+S group (increases of 8.4%, 5.6% and 8.4% in liver weight, HSI and HCI, respectively), and also had higher rates of proliferation of hepatocytes (44.9%). There was also a 27.9% reduction in liver volume density of collagen in the group receiving NHF compared with the group that received saline. This reduction was also observed in gene expression of collagen a1, which was 53%. However, there were no differences in other genes evaluated. Among biochemical parameters, only the alkaline phosphatase showed a reduction. The results indicate that the use of NHF leads to an increase in liver regeneration accompanied by a reduction in the amount of collagen, and these findings, together, can represent a beneficial condition in the recovery of patients with cirrhosis undergoing liver resection

No description available.

Diss. (sammanfattning) Linköping : Linköpings universitet, 2010. / Härtill 6 uppsatser.

INTRODUÇÃO: sangramento por coagulopatia é problema comum durante o transplante hepático (TH). O uso adequado da monitorização da coagulação pode reduzir a transfusão de hemocomponentes, como o Plasma Fresco Congelado (PFC). Exames Convencionais da Coagulação (ECC), tais como Tempo de Protrombina (TP) e Tempo de Tromboplastina Parcial Ativada (TTPa), são os testes mais amplamente utilizados para monitorizar a coagulação durante o TH, mas algumas limitações têm sido apontadas acerca do seu uso em pacientes cirróticos. OBJETIVO: investigar o uso de ECC como variáveis preditoras da indicação de transfusão de PFC durante o TH em pacientes cirróticos. MÉTODO: analisou-se coorte histórica de 297 transplantes hepáticos com enxertos provenientes de doadores cadáveres. Foram incluídos receptores cirróticos de uma única instituição durante nove anos (2002-2010). A infusão profilática de ácido épsilon-aminocaproico (20 mg/kg/h) e outros pré-requisitos hemostáticos foram mantidos na cirurgia. O TP [expresso na forma de Percentual de Atividade da Protrombina (TP%) e de Relação Normalizada Internacional (INR)] e o TTPa foram medidos no pré-operatório e no fim de cada fase do TH. Os participantes só receberam transfusão de PFC quando se diagnosticou coagulopatia, independentemente dos resultados dos ECC. Os pacientes foram distribuídos em dois grupos, de acordo com a ocorrência de transfusão intraoperatória de PFC. Examinou-se o comportamento dos resultados dos ECC durante a cirurgia. Analisaram-se os fatores de risco para a transfusão de PFC por análises uni e multivariada. Os resultados pós-operatórios de ambos os grupos foram comparados. A acurácia dos ECC para predizer o uso de PFC em cada fase da cirurgia foi investigada por curvas ROC. Além disso, pontos de corte dos ECC não associados à coagulopatia foram calculados para cada fase da cirurgia. RESULTADOS: a análise multivariada demonstrou que hematócrito pré-operatório (odds ratio [OR] = 0,90, P < 0,001), fibrinogênio pré-operatório (OR = 0,99, P < 0,001) e ausência de carcinoma hepatocelular (OR = 3,57, P = 0,004) foram as únicas variáveis preditoras independentes para a transfusão de PFC durante o TH. As mortalidades precoce e tardia, a permanência em UTI e a incidência de reoperações por sangramento microvascular foram semelhantes entre os grupos. Os ECC demonstraram baixa acurácia global para a predição de transfusão de PFC durante o TH (as áreas sob as curvas ROC não chegaram a 70%, independentemente do teste da coagulação e do momento da aferição). Pontos de corte de ECC com alta especificidade para a não transfusão de PFC foram determinados em cada fase do TH para TP% (39,4, 27,8 e 20,3), INR (2,14, 2,62 e 3,52) e TTPa (50,5, 80,2 e 119,5 segundos). CONCLUSÕES: os únicos preditores independentes para a transfusão de PFC durante o TH foram hematócrito pré-operatório, fibrinogênio pré-operatório e ausência de carcinoma hepatocelular. Os ECC demonstraram baixa correlação com a transfusão intraoperatória de PFC, independentemente do momento da coleta ou dos pontos de corte adotados / BACKGROUND & AIMS: Bleeding due to coagulopathy is a common problem during liver transplantation (LT). Coagulation monitoring may reduce transfusion of blood components, including Fresh Frozen Plasma (FFP). Conventional coagulation assays (CCA), like Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT), are the most widely employed tests to monitor coagulation during LT, but some limitations have been assigned to their use in cirrhotic patients. This study investigated the predictive value of these blood coagulation tests in predicting FFP transfusions during LT in cirrhotic patients. METHODS: This historical cohort study analyzed 297 isolated, deceased donor LTs performed in cirrhotic patients from a single institution during a nine-year period (2002 - 2010). Prophylactic infusion of epsilon-aminocaproic acid [EACA] (20 mg/kg/h) and other hemostatic requirements were maintained intraoperatively. PT [expressed as Activity Percentage (PT%) and International normalized ratio (INR)] and aPTT [expressed in seconds] were measured preoperatively and by the end of each phase of LT. Hemostatic blood components were transfused only in case of coagulopathy. Patients were divided in two groups according to intraoperative FFP transfusion: FFP group and Non-FFP group. Behavior of CCA results during LT were examined in both groups. Univariate and multivariate analyses of risk factors associated with FFP transfusion were performed. Post-operative outcomes were compared between groups. Accuracy of CCA to predict FFP transfusions was investigated using receiver operating characteristic (ROC) curves. Also, alert values of CCA unassociated with coagulopathy in each phase of surgery were calculated. RESULTS: Multivariate analysis showed that preoperative hematocrit (odds ratio [OR] = 0.90, P < 0.001), preoperative fibrinogen (OR = 0.99, P < 0.001) and absence of hepatocellular carcinoma (OR = 3.57, P = 0.004) were the only significant predictors for FFP transfusion. Short- and long-term survival, ICU stay and incidence of early reoperations for bleeding were similar between the groups. CCA demonstrated poor overall accuracy for predicting FFP transfusions (area under the ROC curves did not reach 0.70, irrespective of assay and of phase of sampling). High-specificity values of CCA unassociated with coagulopathy in each of 3 phases of LT were identified for INR (2.14, 2.62 and 3.52), PT% (39.4, 27.8 and 20.3%) and aPTT (50.5, 80.2 and 119.5 seconds). CONCLUSIONS: the only significant predictors for FFP transfusion were preoperative hematocrit, preoperative fibrinogen and absence of hepatocellular carcinoma. CCA, regardless of adopted cutoffs and of time of sampling during LT, have poor correlation with intraoperative FFP transfusion

A hepatite C é um processo inflamatório do tecido hepático que acomete milhões de pessoas em todo mundo. A evolução crônica da doença pode levar a transformação da fibrose hepática em cirrose e carcinoma hepatocelular em um grande número de casos. A avaliação dos graus de fibrose hepática é importante para o estudo da gravidade e progressão da doença, bem como decisão terapêutica e avaliação de sua eficácia. Os métodos não invasivos de avaliação da fibrose hepática têm sido uma opção aos possíveis riscos da biópsia hepática, ainda considerada o melhor método de avaliação de fibrose hepática. No presente trabalho, 107 pacientes portadores de hepatite C foram submetidos à biópsia hepática e Elastografia transitória hepática, 106 pacientes APRI e FIB4, ELF em 68 pacientes e ARFI em 51 pacientes. Usando a área abaixo da Curva ROC, AUROC, para obter a acurácia da fibrose hepática, encontramos na fibrose significativa ( >= F2): Elastografia transitória hepática: 0,83; FIB4: 0,76; ELF: 0,70; APRI: 0,69; ARFI: 0,67; na fibrose avançada ( >= F3): Elastografia transitória hepática: 0,85; ELF: 0,82; FIB4: 0,77; ARFI: 0,74; APRI: 0,71 e na cirrose ( >= F4) APRI: 1; FIB4: 1; Elastografia transitória hepática: 0,99; ARFI: 0,96; ELF: 0,94. Podemos dizer que em todos os graus de fibrose avaliados, a Elastografia transitória hepática foi o método que apresentou a melhor acurácia. Em se de tratando de cirrose (>=F4), todos os métodos não invasivos apresentam excelente acurácia. Utilizando o método Obuchowski, encontramos em cada grau de fibrose hepática classificado pelo escore METAVIR as acurácias: F1= Elastografia transitória hepática: 0,81; ARFI: 0,78; APRI: 0,72; FIB4: 0,67; ELF: 0,44; F2= Elastografia transitória hepática: 0,73; FIB4: 0,68; ELF: 0,63; APRI: 0,60; ARFI: 0,53; F3= ELF: 0,77; Elastografia transitória hepática: 0,70; FIB4: 0,67; ARFI: 0,64; APRI: 0,60 e F4: APRI e FIB4: 1; Elastografia transitória hepática: 0,98; ARFI: 0,96; ELF: 0,82. A Elastografia transitória hepática se mantém como um método eficiente para todos os graus de fibrose, sendo que nos extremos apresenta discreta superioridade em relação aos graus intermediários. A acurácia de todos os métodos é superior em F4 / Hepatitis C is an inflammatory condition of the hepatic tissue that affects millions worldwide. The chronic stages of the disease turns from hepatic fibrosis into cirrhosis and hepatocellular carcinoma in many cases. The evaluation of fibrosis staging is important for prognosis, as well as understanding the progression of the disease, choice of treatment options and assessing their effectiveness. Non-invasive methods of fibrosis assessment have increasingly become alternatives to liver biopsy, which is still considered the best method of fibrosis assessment. In this study, 107 consecutive patients with hepatitis C virus were submitted to liver biopsy and transient elastography, 106 underwent APRI and FIB-4, 68 underwent ELF and 51 underwent ARFI. Using the area under ROC curve (AUROC) to obtain the degree of accuracy of each test, the following cutoffs were found for significant fibrosis (F >= 2): transient elastography: 0,83; FIB4: 0,76; ELF: 0,70; APRI: 0,69; ARFI: 0,67; For advanced fibrosis (F>=3): transient elastography: 0,85; ELF: 0,82; FIB4: 0,77; ARFI: 0,74; APRI: 0,71; For cirrhosis (F >= 4): APRI: 1; FIB4: 1; transient elastography: 0,99; ARFI: 0,96; ELF: 0,94. Of the methods assessed, transient elastography presented the greatest diagnostic accuracy across all levels of fibrosis. When assessing cirrhosis (F>= 4), all of these non-invasive methods showed excellent diagnostic accuracy. Using the Obuchowski method, the accuracy of each degree of fibrosis categorised by the METAVIR score was determined: F1= transient elastography: 0,81; ARFI: 0,78; APRI: 0,72; FIB4: 0,67; ELF: 0,44; F2=transient elastography: 0,73; FIB4: 0,68; ELF: 0,63; APRI: 0,60; ARFI: 0,53; F3= ELF: 0,77; transient elastography: 0,70; FIB4: 0,67; ARFI: 0,64; APRI: 0,60; F4: APRI and FIB4: 1; transient elastography: 0,98; ARFI: 0,96; ELF: 0,82. Transient elastography remained the most effective method for all degrees of fibrosis, although at the higher levels this superiority was less than at the intermediate levels. The accuracy of all methodologies was best at F >= 4

O presente trabalho avaliou o papel da solução parenteral de fatores hepatotróficos nutricionais em animais com cirrose submetidos à hepatectomia parcial. Este procedimento é temido nestes animais devido à possibilidade de ocorrência de falência hepática aguda, já que a remoção de um fragmento do fígado reduz ainda mais a capacidade funcional de um órgão já comprometido. Além disso, é conhecido que o fígado cirrótico diminui sua capacidade regenerativa, fato que atrasa a recuperação do animal, bem como também regenera cirroticamente. Esses fatores, aliados, contribuem para uma considerável taxa de mortalidade pós-operatória. Porém, há algumas situações em que estes pacientes precisam ser submetidos a ressecções hepáticas, tais como traumas, infecções e neoplasias. De fato, a presença de hepatocarcinomas representa a maior indicação deste procedimento em fígados cirróticos. Por outro lado, tem-se mostrado que a administração parenteral de solução de fatores hepatotróficos nutricionais (FHN), uma mistura de aminoácidos, vitaminas, sais minerais e hormônios, aumenta consideravelmente a proliferação celular e o tamanho do fígado em animais sadios, com fibrose e com cirrose. Nestes dois últimos, além do crescimento hepático, ocorre também uma importante redução na quantidade de colágeno, significando uma melhora morfológica que, por muitas vezes, resulta em uma melhora funcional. Sendo assim, o objetivo do presente trabalho foi o verificar se o uso de fatores hepatotróficos nutricionais traria também uma melhora morfológica e funcional em animais com cirrose induzida por tiocetamida após uma ressecção hepática de 40%. Utilizou-se 40 ratos (Rattus norvegicus) Wistar fêmeas cuja indução da cirrose foi pela administração intraperitoneal de tiocetamida. Ao final deste período, e após 10 dias de descanso, todos os animais foram submetidos a uma hepatectomia parcial (HP) de 40%. Foram então divididos em dois grupos: um que recebeu intraperitonealmente a solução de fatores hepatotróficos nutricionais durante 12 dias, designado grupo HP+FHN, e outro que recebeu solução fisiológica nas mesmas condições, formando o grupo HP+S. Os seguintes parâmetros foram avaliados no término do período experimental: dados biométricos (peso do fígado, IHS: índice hepassomático e IHC: índice hepatocarcaça), bioquímica hepática plasmática (AST, ALT, fosfatase alcalina, bilirrubina total e albumina), quantificação da densidade volumétrica de colágeno hepático por morfometria, quantificação do índice de proliferação celular por imunohistoquímica para PCNA e expressão de genes pró-fibróticos (MMP2, TIMP1, Cola1 e TGFb1) por PCR em tempo real. De fato, os fígados dos animais do grupo HP+FHN estavam maiores do que os animais do grupo HP+S (aumentos de 8,4%, 5,6% e 8,4% no peso do fígado, IHS e IHC respectivamente), e também apresentaram maior índice de proliferação de hepatócitos (44,9%). Ocorreu também redução de 27,9% na densidade volumétrica do colágeno hepático no grupo que recebeu FHN comparandose com o grupo que recebeu solução salina. Esta redução também foi observada na expressão do gene de colágeno a1, que foi de 53%. Porém, não houve diferença nos demais genes avaliados. Dentre os parâmetros bioquímicos, apenas a fosfatase alcalina mostrou redução. Os resultados obtidos permitem concluir que o uso de FHN acarreta em um aumento da regeneração hepática acompanhado de uma redução da quantidade de colágeno e, esses achados, em conjunto, podem representar uma condição benéfica na recuperação de pacientes com cirrose submetidos à ressecção hepática / The current study evaluated the role of parenteral solution of nutritional hepatotrophic factors in animals with cirrhosis undergoing partial hepatectomy. This procedure is fearful in these animals due to the possibility of acute liver failure, since removal of a liver fragment further reduces the functional capacity of an already compromised organ. Moreover, it is known that cirrhotic liver decreases its regenerative capacity, which impairs the recovery of the animal, and also regenerates cirrhotic. These factors, together, contribute to a considerable rate of postoperative mortality. However, there are some situations when these patients need to be submitted to liver resection, such as trauma, infections and neoplasm. In fact, the presence of hepatocellular carcinoma represents the most important indication of this procedure in patients with cirrhosis. On the other hand, it has been shown that parenteral administration of a solution of the nutritional hepatotrophic factors (NHF), a mixture of amino acids, vitamins, minerals and hormones, significantly increases cell proliferation and liver size in healthy, fibrotic and cirrhotic animals. In the two latter, beyond the liver growth, there is also a significant reduction in the amount of collagen, meaning a morphological enhancement, resulting in a functional improvement. Therefore, the objective of this study was to determine whether the use of nutritional hepatotrophic factors would also lead a morphological and functional improvement in animals with thioacetamide-induced cirrhosis after 40% liver resection. We used 40 rats (Rattus norvegicus) female Wistar whose cirrhosis was induced by intraperitoneal administration thioacetamide. At the end of this period, and after 10 days of rest, all animals were underwent a partial hepatectomy (PH) of 40%. They were then divided into two groups: one that received intraperitoneally a solution of nutritional hepatotrophic factors for 12 days, designated PH+NHF group, and another that received saline under the same conditions, forming the PH+S group. The following parameters were evaluated at the end of the trial period: biometrics (liver weight, HSI hepatossomatic index, and HCI hepatocarcass index), plasmatic liver biochemistry (AST, ALT, alkaline phosphatase, total bilirubin and albumin), quantification of volume density of collagen in liver morphology, quantification of cell proliferation by immunohistochemistry for PCNA and expression of pro-fibrotic genes (MMP2, TIMP1, TGF1 and Cola1) by real-time PCR. In fact, the livers of animals in group PH+NHF were larger than the animals in PH+S group (increases of 8.4%, 5.6% and 8.4% in liver weight, HSI and HCI, respectively), and also had higher rates of proliferation of hepatocytes (44.9%). There was also a 27.9% reduction in liver volume density of collagen in the group receiving NHF compared with the group that received saline. This reduction was also observed in gene expression of collagen a1, which was 53%. However, there were no differences in other genes evaluated. Among biochemical parameters, only the alkaline phosphatase showed a reduction. The results indicate that the use of NHF leads to an increase in liver regeneration accompanied by a reduction in the amount of collagen, and these findings, together, can represent a beneficial condition in the recovery of patients with cirrhosis undergoing liver resection